Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Mizuho Securities Reiterates Neutral Rating on Eli Lilly (LLY)
February 11, 2020 7:19 AM ESTMizuho Securities analyst Vamil Divan reiterated a Neutral rating and $148.00 price target on Eli Lilly (NYSE: LLY) following the company's announcement that the DIAN-TU study did not meet the primary endpoint of showing an improvement for the drug over placebo. Divan believes some... More
